NUV-868 is under clinical development by Nuvation Bio and currently in Phase II for Triple-Negative Breast Cancer (TNBC).
CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.
Anti-CDH17 CAR-T Cells is under clinical development by UTC Therapeutics and currently in Phase I for Pancreatic Cancer.
The therapeutic candidate is under development for the treatment of ovarian cancer. It comprises of induced pluripotent stem (iPS) cell derived natural killer (iNK) cell.
NA-731 is under clinical development by Biomed Industries and currently in Phase I for Traumatic Brain Injury.
RG-6540 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Primary Mediastinal B-Cell Lymphoma.
Alphaf-001 is under clinical development by Alpha Fusion and currently in Phase I for Follicular Thyroid Cancer.
COVID-19 (omicron JN.1) vaccine is under clinical development by Moderna and currently in Pre-Registration for Coronavirus Disease 2019 (COVID-19).
BM-219 is under clinical development by Suzhou Biomissile Biopharmaceutical and currently in Phase I for Coronavirus Disease 2019 (COVID-19).
Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...